L Servaas Dolmans1, Frans H Rutten2, Niels C T Koenen2, Marie-Louise E L Bartelink2, Johannes B Reitsma2, L Jaap Kappelle3, Arno W Hoes2. 1. Julius Center for Health Sciences and Primary Care, University Medical Center, Utrecht University, Utrecht, The Netherlands, l.s.dolmans@umcutrecht.nl. 2. Julius Center for Health Sciences and Primary Care, University Medical Center, Utrecht University, Utrecht, The Netherlands. 3. Department of Neurology, University Medical Center, Utrecht University, Utrecht, The Netherlands.
Abstract
BACKGROUND AND PURPOSE: A rapid serum biomarker that confirms or rules out a transient ischemic attack (TIA) would be of great value in clinical practice. We aimed to systematically review current evidence for the diagnostic accuracy of blood biomarkers in the early diagnosis of TIA. METHODS: This is a systematic review with quality appraisal of individual studies using the QUADAS-2 tool. MEDLINE and EMBASE databases were searched up to May 1, 2017, to select primary diagnostic accuracy studies evaluating potential biomarkers in blood for the diagnosis of TIA or ischemic stroke. RESULTS: Of 4,215 studies retrieved, 78 met our eligibility criteria. Forty-five studies restricted their population to ischemic stroke patients, 32 included both TIA and ischemic stroke patients, and only one study was restricted to TIA patients. In total 62/78 (79.5%) studies had a case-control design comparing TIA or stroke patients with healthy subjects. Overall, 125 single biomarkers and 5 biomarker panels were studied, with a median number of participants per study of 92.0 (interquartile range 44.8-144.5), varying from 8 to 915. Sufficient information to extract 2 × 2 tables was available for 35 (44.9%) articles, and for 60 (48.0 %) biomarkers. Several markers, such as NR2A/B (antibodies), Parkinson 7, nucleoside diphosphate kinase A, ubiquitin fusion degradation protein-1, and heart-type fatty acid binding protein, have shown moderate to high diagnostic accuracy in multiple studies. CONCLUSIONS: Although the methodological quality of studies evaluating biomarkers of brain ischemia was poor, several biomarkers have shown the potential to detect transient brain ischemia in an early phase. Diagnostic accuracy studies in suspected cases of TIA are needed to determine their true clinical value.
BACKGROUND AND PURPOSE: A rapid serum biomarker that confirms or rules out a transient ischemic attack (TIA) would be of great value in clinical practice. We aimed to systematically review current evidence for the diagnostic accuracy of blood biomarkers in the early diagnosis of TIA. METHODS: This is a systematic review with quality appraisal of individual studies using the QUADAS-2 tool. MEDLINE and EMBASE databases were searched up to May 1, 2017, to select primary diagnostic accuracy studies evaluating potential biomarkers in blood for the diagnosis of TIA or ischemic stroke. RESULTS: Of 4,215 studies retrieved, 78 met our eligibility criteria. Forty-five studies restricted their population to ischemic strokepatients, 32 included both TIA and ischemic strokepatients, and only one study was restricted to TIApatients. In total 62/78 (79.5%) studies had a case-control design comparing TIA or strokepatients with healthy subjects. Overall, 125 single biomarkers and 5 biomarker panels were studied, with a median number of participants per study of 92.0 (interquartile range 44.8-144.5), varying from 8 to 915. Sufficient information to extract 2 × 2 tables was available for 35 (44.9%) articles, and for 60 (48.0 %) biomarkers. Several markers, such as NR2A/B (antibodies), Parkinson 7, nucleoside diphosphate kinase A, ubiquitin fusion degradation protein-1, and heart-type fatty acid binding protein, have shown moderate to high diagnostic accuracy in multiple studies. CONCLUSIONS: Although the methodological quality of studies evaluating biomarkers of brain ischemia was poor, several biomarkers have shown the potential to detect transient brain ischemia in an early phase. Diagnostic accuracy studies in suspected cases of TIA are needed to determine their true clinical value.
Authors: Alessandro Liberati; Douglas G Altman; Jennifer Tetzlaff; Cynthia Mulrow; Peter C Gøtzsche; John P A Ioannidis; Mike Clarke; P J Devereaux; Jos Kleijnen; David Moher Journal: PLoS Med Date: 2009-07-21 Impact factor: 11.069
Authors: Svetlana A Dambinova; Guerman A Khounteev; Galina A Izykenova; Igor G Zavolokov; Anna Y Ilyukhina; Alexander A Skoromets Journal: Clin Chem Date: 2003-10 Impact factor: 8.327
Authors: J Donald Easton; Jeffrey L Saver; Gregory W Albers; Mark J Alberts; Seemant Chaturvedi; Edward Feldmann; Thomas S Hatsukami; Randall T Higashida; S Claiborne Johnston; Chelsea S Kidwell; Helmi L Lutsep; Elaine Miller; Ralph L Sacco Journal: Stroke Date: 2009-05-07 Impact factor: 7.914
Authors: Anne W S Rutjes; Johannes B Reitsma; Marcello Di Nisio; Nynke Smidt; Jeroen C van Rijn; Patrick M M Bossuyt Journal: CMAJ Date: 2006-02-14 Impact factor: 8.262
Authors: Svetlana A Dambinova; Kerstin Bettermann; Theodore Glynn; Matthew Tews; David Olson; Joseph D Weissman; Richard L Sowell Journal: PLoS One Date: 2012-07-27 Impact factor: 3.240
Authors: Harsh Goel; Joshua Melot; Matthew D Krinock; Ashish Kumar; Sunil K Nadar; Gregory Y H Lip Journal: Ann Med Date: 2020-08-04 Impact factor: 4.709
Authors: Louis Servaas Dolmans; Frans Rutten; Marie-Louise E L Bartelink; Ewoud J van Dijk; Paul J Nederkoorn; Jaap Kappelle; Arno W Hoes Journal: BMJ Open Date: 2019-10-17 Impact factor: 2.692